Cargando…

Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine

BACKGROUND: Immunotherapy is an evolving therapeutic modality for the treatment of warts. We conducted a study to assess the efficacy and safety of intralesional Mycobacterium w vaccine for the treatment of warts at sites that were difficult to treat. MATERIALS AND METHODS: Thirty patients with at l...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Shilpa, Baveja, Sukriti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338463/
https://www.ncbi.nlm.nih.gov/pubmed/25722598
http://dx.doi.org/10.4103/0974-2077.150740
_version_ 1782481219467870208
author Garg, Shilpa
Baveja, Sukriti
author_facet Garg, Shilpa
Baveja, Sukriti
author_sort Garg, Shilpa
collection PubMed
description BACKGROUND: Immunotherapy is an evolving therapeutic modality for the treatment of warts. We conducted a study to assess the efficacy and safety of intralesional Mycobacterium w vaccine for the treatment of warts at sites that were difficult to treat. MATERIALS AND METHODS: Thirty patients with at least one wart present on either the plantar surface of their feet, palms, volar aspect of their fingers, or periungual or subungual region, were treated with 0.1 ml of killed Mycobacterium w vaccine given intralesionally in a single wart, without any prior sensitisation dose. Thereafter, a single injection of 0.1 ml of vaccine was given at intervals of four weeks in a single wart till there was complete resolution of the warts or a maximum of 10 injections. Treatment was stopped if there was no response after three injections. The patients were followed up for at least six months. RESULTS: Out of the 30 patients, 28 (93.33%) patients had complete resolution of their warts, both at the injected and distant sites. The mean (SD) time for complete clearance of warts was 43.71(32.82) days and the mean (SD) dose of vaccine that was required for complete clearance of warts was 0.186 ml (0.101). Four patients (14.28%) had a recurrence of warts. The treatment was well-tolerated and the side effects were reversible in the majority of the patients. CONCLUSION: In comparison to the earlier studies using Mycobacterium w vaccine for the treatment of warts, our study was different in the following aspects: No sensitisation dose was given, only a single wart was injected at a time and the duration between the period of injections was increased to four weeks. With all these changes we eliminated the complications due to the sensitisation dose and achieved good results. This study provides new insight into the dose and schedule of treatment of this evolving therapeutic modality.
format Online
Article
Text
id pubmed-4338463
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-43384632015-02-26 Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine Garg, Shilpa Baveja, Sukriti J Cutan Aesthet Surg Original Article BACKGROUND: Immunotherapy is an evolving therapeutic modality for the treatment of warts. We conducted a study to assess the efficacy and safety of intralesional Mycobacterium w vaccine for the treatment of warts at sites that were difficult to treat. MATERIALS AND METHODS: Thirty patients with at least one wart present on either the plantar surface of their feet, palms, volar aspect of their fingers, or periungual or subungual region, were treated with 0.1 ml of killed Mycobacterium w vaccine given intralesionally in a single wart, without any prior sensitisation dose. Thereafter, a single injection of 0.1 ml of vaccine was given at intervals of four weeks in a single wart till there was complete resolution of the warts or a maximum of 10 injections. Treatment was stopped if there was no response after three injections. The patients were followed up for at least six months. RESULTS: Out of the 30 patients, 28 (93.33%) patients had complete resolution of their warts, both at the injected and distant sites. The mean (SD) time for complete clearance of warts was 43.71(32.82) days and the mean (SD) dose of vaccine that was required for complete clearance of warts was 0.186 ml (0.101). Four patients (14.28%) had a recurrence of warts. The treatment was well-tolerated and the side effects were reversible in the majority of the patients. CONCLUSION: In comparison to the earlier studies using Mycobacterium w vaccine for the treatment of warts, our study was different in the following aspects: No sensitisation dose was given, only a single wart was injected at a time and the duration between the period of injections was increased to four weeks. With all these changes we eliminated the complications due to the sensitisation dose and achieved good results. This study provides new insight into the dose and schedule of treatment of this evolving therapeutic modality. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4338463/ /pubmed/25722598 http://dx.doi.org/10.4103/0974-2077.150740 Text en Copyright: © Journal of Cutaneous and Aesthetic Surgery http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Garg, Shilpa
Baveja, Sukriti
Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine
title Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine
title_full Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine
title_fullStr Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine
title_full_unstemmed Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine
title_short Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine
title_sort intralesional immunotherapy for difficult to treat warts with mycobacterium w vaccine
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338463/
https://www.ncbi.nlm.nih.gov/pubmed/25722598
http://dx.doi.org/10.4103/0974-2077.150740
work_keys_str_mv AT gargshilpa intralesionalimmunotherapyfordifficulttotreatwartswithmycobacteriumwvaccine
AT bavejasukriti intralesionalimmunotherapyfordifficulttotreatwartswithmycobacteriumwvaccine